Clinical Trial Update: Node-sparing Short-Course Radiation Combined With CAPOX and Tislelizumab for MSS Rectal Cancer [Phase 3]

View source ↗

Summary

A Phase 3 study evaluating node-sparing short-course radiation combined with CAPOX and tislelizumab for MSS rectal cancer. The trial is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rectal Cancer

Drugs mentioned

• Capecitabine (capecitabine)
• OXALIPLATIN (Oxaliplatin)
• Tislelizumab (tislelizumab)

Snippet

Sponsor: Sir Run Run Shaw Hospital | Conditions: Rectal Cancer | Phase 3 | Status: RECRUITING